Sign in Subscribe

Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion

Jazz Pharmaceuticals acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments.

Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion
Credit: Actio Biosciences
Already have an account? Sign in.